[go: up one dir, main page]

FI900087L - Menetelmä atsitromysiinidihydraatin valmistamiseksi - Google Patents

Menetelmä atsitromysiinidihydraatin valmistamiseksi Download PDF

Info

Publication number
FI900087L
FI900087L FI900087A FI900087A FI900087L FI 900087 L FI900087 L FI 900087L FI 900087 A FI900087 A FI 900087A FI 900087 A FI900087 A FI 900087A FI 900087 L FI900087 L FI 900087L
Authority
FI
Finland
Prior art keywords
azithromycin dihydrate
preparing azithromycin
preparing
dihydrate
azithromycin
Prior art date
Application number
FI900087A
Other languages
English (en)
Swedish (sv)
Other versions
FI91263B (fi
FI900087A0 (fi
FI91263C (fi
Inventor
Douglas John Meldrum Allen
Kevin Michael Nepveux
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22202456&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=FI900087(L) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Pfizer filed Critical Pfizer
Publication of FI900087A0 publication Critical patent/FI900087A0/fi
Publication of FI900087L publication Critical patent/FI900087L/fi
Publication of FI91263B publication Critical patent/FI91263B/fi
Application granted granted Critical
Publication of FI91263C publication Critical patent/FI91263C/fi

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H17/00—Compounds containing heterocyclic radicals directly attached to hetero atoms of saccharide radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/52—Two oxygen atoms
    • C07D239/54—Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals
    • C07D239/545—Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals with other hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H17/00—Compounds containing heterocyclic radicals directly attached to hetero atoms of saccharide radicals
    • C07H17/04—Heterocyclic radicals containing only oxygen as ring hetero atoms
    • C07H17/08—Hetero rings containing eight or more ring members, e.g. erythromycins

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Cardiology (AREA)
  • Biotechnology (AREA)
  • Pulmonology (AREA)
  • Oncology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Communicable Diseases (AREA)
  • Immunology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Saccharide Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
FI900087A 1987-07-09 1990-01-08 Menetelmä atsitromysiinidihydraatin valmistamiseksi FI91263C (fi)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
PCT/US1987/001612 WO1989000576A1 (en) 1987-07-09 1987-07-09 Azithromycin dihydrate
US8701612 1987-07-09

Publications (4)

Publication Number Publication Date
FI900087A0 FI900087A0 (fi) 1990-01-08
FI900087L true FI900087L (fi) 1990-01-08
FI91263B FI91263B (fi) 1994-02-28
FI91263C FI91263C (fi) 1994-06-10

Family

ID=22202456

Family Applications (1)

Application Number Title Priority Date Filing Date
FI900087A FI91263C (fi) 1987-07-09 1990-01-08 Menetelmä atsitromysiinidihydraatin valmistamiseksi

Country Status (45)

Country Link
US (1) US6268489B1 (fi)
EP (1) EP0298650B1 (fi)
JP (1) JPH0631300B2 (fi)
KR (1) KR900006218B1 (fi)
CN (1) CN1016785B (fi)
AP (1) AP44A (fi)
AR (1) AR243532A1 (fi)
AT (1) ATE72446T1 (fi)
AU (1) AU604553B2 (fi)
BA (1) BA98213B1 (fi)
BG (1) BG47348A3 (fi)
CA (1) CA1314876C (fi)
CS (1) CS272241B2 (fi)
CY (1) CY1776A (fi)
DD (1) DD271705A5 (fi)
DE (1) DE3868296D1 (fi)
DK (1) DK172573B1 (fi)
EG (1) EG18527A (fi)
ES (1) ES2038756T3 (fi)
FI (1) FI91263C (fi)
GR (1) GR3003737T3 (fi)
HK (1) HK127594A (fi)
HU (1) HU211862A9 (fi)
IE (1) IE60354B1 (fi)
IL (1) IL86979A (fi)
IN (1) IN168879B (fi)
IS (1) IS1540B (fi)
LV (1) LV10624B (fi)
MA (1) MA21323A1 (fi)
MX (1) MX12213A (fi)
MY (1) MY103744A (fi)
NO (1) NO171556C (fi)
NZ (1) NZ225338A (fi)
OA (1) OA08743A (fi)
PH (1) PH30953A (fi)
PL (1) PL157145B1 (fi)
PT (1) PT87933B (fi)
RO (1) RO107257B1 (fi)
RU (1) RU2066324C1 (fi)
SG (1) SG27794G (fi)
SI (1) SI8811325A8 (fi)
UA (1) UA27040C2 (fi)
WO (1) WO1989000576A1 (fi)
YU (1) YU45075B (fi)
ZA (1) ZA884925B (fi)

Families Citing this family (76)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HRP20020231A2 (en) * 2002-03-18 2003-12-31 Pliva D D ISOSTRUCTURAL PSEUDOPOLYMORPHS OF 9-DEOXO-9a-AZA-9a-METHYL-9a-HOMOERYTHROMYCIN A
US5912331A (en) * 1991-03-15 1999-06-15 Merck & Co., Inc. Process for the preparation of 9-deoxo-9(Z)-hydroxyiminoerythromycin A
US5985844A (en) * 1992-03-26 1999-11-16 Merck & Co., Inc. Homoerythromycin A derivatives modified at the 4"-and 8A-positions
US5189159A (en) * 1992-04-02 1993-02-23 Merck & Co., Inc. 8a-AZA-8a-homoerythromycin cyclic iminoethers
EP0539223A1 (en) * 1991-10-25 1993-04-28 Ono Pharmaceutical Co., Ltd. Glycine derivative monosodium salt tetrahydrate having an inhibitory effect on elastase
US5215980A (en) * 1992-01-17 1993-06-01 Merck & Co., Inc. 10-AZA-9-deoxo-11-deoxy-erythromycin A and derivatives thereof
US5210235A (en) * 1992-08-26 1993-05-11 Merck & Co., Inc. Methods of elaborating erythromycin fragments into amine-containing fragments of azalide antibiotics
US5332807A (en) * 1993-04-14 1994-07-26 Merck & Co., Inc. Process of producing 8A- and 9A-azalide antibiotics
CN1034734C (zh) * 1993-12-10 1997-04-30 北京市集才药物研究所 一种新的阿齐红霉素结晶及其制备方法
US5605889A (en) 1994-04-29 1997-02-25 Pfizer Inc. Method of administering azithromycin
US6068859A (en) 1994-05-06 2000-05-30 Pfizer Inc. Controlled-release dosage forms of Azithromycin
ES2122905B1 (es) * 1996-07-11 1999-11-16 Astur Pharma Sa Sintesis de 11,12-hidrogenoortoborato de 9-desoxo-9a-aza-11,12-desoxi-9a-metil-9a-homoeritromicina a. un procedimiento para la preparacion de 9-desoxo-9a-aza-9a-metil-9a-homoeritromicina a dihidrato (azitromicina dihidrato).
ES2279242T3 (es) * 1997-10-16 2007-08-16 Glaxosmithkline Istrazivacki Centar Zagreb D.O.O. Nuevos 3,6-hemicetales de la clase de las 9a-azalidas.
US6861411B1 (en) 1997-12-02 2005-03-01 Pfizer, Inc. Method of treating eye infections with azithromycin
PT102130A (pt) * 1998-03-13 1999-09-30 Hovione Sociedade Quimica S A Processo de preparacao de dihidrato de azitromicina
TW546302B (en) * 1998-05-08 2003-08-11 Biochemie Sa Improvements in macrolide production
CA2245398C (en) * 1998-08-21 2002-01-29 Apotex Inc. Azithromycin monohydrate isopropanol clathrate and methods for the manufacture thereof
EP1484062A1 (en) * 1998-11-30 2004-12-08 Teva Pharmaceutical Industries Limited Crystalline azithromycin, process for manufacture and pharmaceutical compositions thereof
US7056893B2 (en) 1999-03-31 2006-06-06 Insite Vision, Inc. Topical treatment for prevention of ocular infections
US6239113B1 (en) 1999-03-31 2001-05-29 Insite Vision, Incorporated Topical treatment or prevention of ocular infections
CA2372206C (en) * 1999-05-18 2006-01-10 Pfizer Products Inc. Novel crystalline forms of a macrolide antibiotic
ES2267549T3 (es) * 1999-06-29 2007-03-16 Sandoz Ag Procedimiento para la produccion de azitromicina.
ES2177373B1 (es) 1999-11-26 2003-11-01 Astur Pharma Sa Preparacion de azitromicina en su forma no cristalina
PT1246831E (pt) 2000-01-04 2008-03-28 Teva Pharma Método de preparação de di-hidrato de azitromicina
ES2162764B1 (es) * 2000-05-17 2003-04-01 Ercros Ind Sa Forma polimorfica del dihidrato de azitromicina, y su procedimiento deobtencion.
ES2260047T3 (es) 2000-07-25 2006-11-01 Laboratorio Silanes, S.A. De C.V. Proceso de etapa unica para la preparacion de 7,16-deoxi-2-aza-10-o-cladinosil-12-o-desosaminil-4,5-dihidroxi-6-etil-3,5,9,11,13,15-hexametilbiciclo(11.2.1)hexadeca-1(2)-en-ona y obtencion de una forma nueva de 9-deoxo-9a-metil-9a-homoeritromicina a.
ES2172417B1 (es) * 2000-07-31 2003-09-16 Sint Quimica Sa Nueva forma mejorada de azitromicina monohidrato de menor higroscopicidad, procedimiento de preparacion y composiciones farmaceuticas que la comprenden.
CA2419873A1 (en) 2000-08-23 2002-02-28 Wockhardt Limited Process for preparation of anhydrous azithromycin
KR100815163B1 (ko) * 2000-11-27 2008-03-19 바이오케미 에스.에이. 마크로라이드 용매화물
IN190080B (fi) * 2001-01-29 2003-06-07 Alembic Ltd
KR100491183B1 (ko) * 2001-03-21 2005-05-25 한미약품 주식회사 아지트로마이신의 제조방법 및 이 방법에 사용되는9-데옥소-9에이-아자-9에이-호모에리트로마이신 에이의결정성 수화물
US6861413B2 (en) 2001-05-22 2005-03-01 Pfizer Inc. Stable non-dihydrate azithromycin oral suspensions
EP1671979B1 (en) 2001-05-22 2008-08-13 Pfizer Products Inc. New Cristal Form of Azithromycin
JP2004530703A (ja) * 2001-05-22 2004-10-07 ファイザー・プロダクツ・インク 結晶形アジスロマイシン
JP2005501862A (ja) * 2001-08-21 2005-01-20 ファイザー・プロダクツ・インク １回限りの投与量のアジスロマイシン
PL371259A1 (en) * 2001-12-21 2005-06-13 Pfizer Products Inc. Directly compressible formulations of azithromycin
WO2003053399A2 (en) * 2001-12-21 2003-07-03 Pfizer Products Inc. Methods for wet granulating azithromycin
MXPA04007427A (es) * 2002-02-01 2004-10-11 Pfizer Prod Inc Formulaciones de azitromicina granuladas por via seca.
US7376064B2 (en) 2002-02-25 2008-05-20 Samsung Electronics Co., Ltd. Method and apparatus for recording data on optical recording medium
ITMI20021209A1 (it) * 2002-06-04 2003-12-04 Chemi Spa Processo di preparazione di azitromicina ad elevata purezza
US6855813B2 (en) * 2002-07-19 2005-02-15 Alembic Limited Process for the preparation of azithromycin monohydrate
HRP20020614A2 (en) 2002-07-22 2004-06-30 PLIVA-ISTRAŽIVAČKI INSTITUT d.o.o. Rhombic pseudopolymorph of 9-deoxo-9a-aza-9a-methyl-9a-homoerythromycin a
GB2395482A (en) * 2003-07-03 2004-05-26 Jubilant Organosys Ltd Process for preparing non-hygroscopic azithromycin dihydrate
US20050013835A1 (en) * 2003-07-15 2005-01-20 Pfizer Inc. Stable non-dihydrate azithromycin oral suspensions
WO2005053652A1 (en) 2003-12-04 2005-06-16 Pfizer Products Inc. Multiparticulate crystalline drug compositions containing a poloxamer and a glyceride
WO2005053651A1 (en) * 2003-12-04 2005-06-16 Pfizer Products Inc. Multiparticulate compositions with improved stability
US6984403B2 (en) * 2003-12-04 2006-01-10 Pfizer Inc. Azithromycin dosage forms with reduced side effects
WO2005053639A2 (en) * 2003-12-04 2005-06-16 Pfizer Products Inc. Controlled release multiparticulates formed with dissolution enhancers
CA2547774A1 (en) * 2003-12-04 2005-06-16 Pfizer Products Inc. Method for making pharmaceutical multiparticulates
JP2007513143A (ja) * 2003-12-04 2007-05-24 ファイザー・プロダクツ・インク 押出機を使用して好ましくはポロクサマーおよびグリセリドを含む多粒子アジスロマイシン組成物を製造するための噴霧凝固法
CN1889933A (zh) * 2003-12-04 2007-01-03 辉瑞产品公司 由基于液体的工艺制备的阿奇霉素多颗粒剂型
JP2007513147A (ja) * 2003-12-04 2007-05-24 ファイザー・プロダクツ・インク 押し出し機を使用して、好ましくはポロキサマーとグリセリドを含有する多粒子結晶性医薬組成物を製造するための噴霧凝結方法
US20060116336A1 (en) * 2004-03-17 2006-06-01 American Pharmaceutical Partners, Inc. Lyophilized azithromycin formulation
US7468428B2 (en) 2004-03-17 2008-12-23 App Pharmaceuticals, Llc Lyophilized azithromycin formulation
US7235646B2 (en) 2004-06-28 2007-06-26 Alembic Limited Process for the preparation of azithromycin monohydrate isopropanol clathrate
CN1308361C (zh) * 2004-08-09 2007-04-04 大连振邦氟涂料股份有限公司 乙烯－三氟氯乙烯共聚物的制备方法
US7683162B2 (en) * 2004-08-30 2010-03-23 Taro Pharmaceutical Industries Limited Process of preparing a crystalline azithromycin monohydrate
EP1817315A1 (en) * 2004-12-01 2007-08-15 Teva Gyógyszergyár Zártköruen Muködo Részvenytarsaság Processes for producing crystalline macrolides
US20080199527A1 (en) * 2004-12-21 2008-08-21 Pfizer Inc. Enteric Coated Azithromycin Multiparticulates
US8546423B2 (en) 2005-05-18 2013-10-01 Mpex Pharmaceuticals, Inc. Aerosolized fluoroquinolones and uses thereof
CN100366686C (zh) * 2006-01-12 2008-02-06 济南瑞氟化工科技有限公司 一种氟硅超双疏不粘涂料
US20070281894A1 (en) * 2006-06-05 2007-12-06 Auspex Pharmaceuticals, Inc. Preparation and utility of substituted erythromycin analogs
US7704959B2 (en) 2006-10-03 2010-04-27 Dow Pharmaceutical Sciences Azithromycin for the treatment of nodular acne
US20090062220A1 (en) * 2007-08-29 2009-03-05 Protia, Llc Deuterium-enriched azithromycin
CN101177441B (zh) * 2007-12-05 2012-05-23 浙江耐司康药业有限公司 一种稳定的阿奇霉素一水合物结晶的制备方法
CN101624412B (zh) 2008-07-10 2012-07-04 刘力 大环内酯类衍生物及其制备和用途
JP2012505222A (ja) 2008-10-07 2012-03-01 エムペックス・ファーマシューティカルズ・インコーポレーテッド 肺炎症を低減するためのレボフロキサシンの吸入
JP2012505223A (ja) 2008-10-07 2012-03-01 エムペックス・ファーマシューティカルズ・インコーポレーテッド 薬物動態の改善のためのエアゾールフルオロキノロン配合物
CN101418026B (zh) * 2008-10-09 2011-05-18 南京工业大学 一种晶型和粒度可控的阿奇霉素结晶工艺
CN101787063B (zh) * 2009-01-23 2012-12-19 刘力 抗感染药物及其制备和用途
EP2405909A1 (en) 2009-03-13 2012-01-18 Da Volterra Compositions and methods for elimination of gram-negative bacteria
KR20120100904A (ko) 2009-09-04 2012-09-12 엠펙스 파마슈티컬즈, 인코포레이티드 낭포성 섬유증을 치료하기 위한 에어로졸화된 레보플록사신의 용도
CN102911219A (zh) * 2011-08-03 2013-02-06 山东方明药业集团股份有限公司 一种阿齐霉素在水相直接结晶的方法
CN103159811A (zh) * 2011-12-10 2013-06-19 山东方明药业集团股份有限公司 一种阿齐霉素中间体9a-脱氧-9a-氮杂-9a-高红霉素A的制备方法
WO2013088274A1 (en) 2011-12-14 2013-06-20 Wockhardt Limited Anhydrous amorphous azithromycin composition free of azithromycin dihydrate
CN102417531B (zh) * 2011-12-20 2014-06-11 浙江国邦药业有限公司 一种阿奇霉素一水合物的制备方法

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4020270A (en) * 1974-05-02 1977-04-26 Societa' Farmaceutici Italia S.P.A. L-lyxohex-1-enopyranose derivative
US4219641A (en) * 1979-06-14 1980-08-26 The Upjohn Company Process for preparing erythromycin succinate
YU43006B (en) 1981-03-06 1989-02-28 Pliva Pharm & Chem Works Process for preparing n-methyl-11-aza-10-deoxo-10-dihydro erythromycin and derivatives thereof
US4474768A (en) * 1982-07-19 1984-10-02 Pfizer Inc. N-Methyl 11-aza-10-deoxo-10-dihydro-erytromycin A, intermediates therefor
US4526889A (en) * 1982-11-15 1985-07-02 Pfizer Inc. Epimeric azahomoerythromycin A derivative, intermediates and method of use
PH19293A (en) * 1982-11-15 1986-03-04 Pfizer Epimeric azahomoerythromycin,pharmaceutical composition containing the same and method of use thereof
US4512982A (en) * 1984-04-13 1985-04-23 Pfizer Inc. 9α-Aza-9α-homoerythromycin compounds, pharmaceutical composition and therapeutic method
YU43402B (en) * 1985-03-04 1989-06-30 Pliva Pharm & Chem Works Process for preparation of 11-aza-10-deoxo-10-dihydroeritromycin "a" by using electro-chemical reduction
WO1989002271A1 (en) 1987-09-10 1989-03-23 Pfizer Azithromycin and derivatives as antiprotozoal agents

Also Published As

Publication number Publication date
IS1540B (is) 1994-01-28
WO1989000576A1 (en) 1989-01-26
SI8811325A8 (en) 1996-12-31
MA21323A1 (fr) 1989-04-01
CN1016785B (zh) 1992-05-27
NO171556C (no) 1993-03-31
DK172573B1 (da) 1999-01-25
IN168879B (fi) 1991-06-29
EG18527A (en) 1993-10-30
SG27794G (en) 1994-10-14
FI91263B (fi) 1994-02-28
CS489688A2 (en) 1990-03-14
DD271705A5 (de) 1989-09-13
FI900087A0 (fi) 1990-01-08
IS3370A7 (is) 1989-01-10
KR900006218B1 (ko) 1990-08-25
DK380688D0 (da) 1988-07-08
BG47348A3 (bg) 1990-06-15
US6268489B1 (en) 2001-07-31
ZA884925B (en) 1990-02-28
CS272241B2 (en) 1991-01-15
HK127594A (en) 1994-11-25
IE882108L (en) 1989-01-09
PL273590A1 (en) 1989-03-20
YU132588A (en) 1990-02-28
MY103744A (en) 1993-09-30
AP8800093A0 (en) 1988-05-01
AU604553B2 (en) 1990-12-20
LV10624B (en) 1995-10-20
NO900077D0 (no) 1990-01-08
NZ225338A (en) 1990-02-26
ATE72446T1 (de) 1992-02-15
BA98213B1 (bs) 1999-08-02
NO900077L (no) 1990-01-08
PT87933A (pt) 1989-06-30
CN1030422A (zh) 1989-01-18
PL157145B1 (en) 1992-04-30
DE3868296D1 (de) 1992-03-19
PH30953A (en) 1997-12-23
IE60354B1 (en) 1994-06-29
JPS6438096A (en) 1989-02-08
LV10624A (lv) 1995-04-20
MX12213A (es) 1993-05-01
CA1314876C (en) 1993-03-23
RU2066324C1 (ru) 1996-09-10
ES2038756T3 (es) 1993-08-01
AP44A (en) 1989-07-27
DK380688A (da) 1989-01-10
HU211862A9 (en) 1995-12-28
OA08743A (fr) 1989-03-31
EP0298650A3 (en) 1989-11-08
UA27040C2 (uk) 2000-02-28
CY1776A (en) 1995-10-20
KR890002137A (ko) 1989-04-08
YU45075B (en) 1991-08-31
FI91263C (fi) 1994-06-10
NO171556B (no) 1992-12-21
AU1883988A (en) 1989-01-12
GR3003737T3 (fi) 1993-03-16
IL86979A (en) 1992-11-15
EP0298650A2 (en) 1989-01-11
IL86979A0 (en) 1988-12-30
EP0298650B1 (en) 1992-02-05
JPH0631300B2 (ja) 1994-04-27
AR243532A1 (es) 1993-08-31
RO107257B1 (ro) 1993-10-30
PT87933B (pt) 1994-09-30

Similar Documents

Publication Publication Date Title
FI900087L (fi) Menetelmä atsitromysiinidihydraatin valmistamiseksi
PT88596A (pt) Process for preparing 2-anilinopyrimidine derivatives useful aspesticidas
PT86866A (pt) Process for preparing piperazinyl-heterocyclic compounds
FI893929L (fi) Menetelmä stabiilin sinkki-protamiini- -interferonikompleksin valmistamiseksi
FI885816L (fi) Menetelmä taikinan parantamiseksi
PL270238A1 (en) Method for manufacturing avermectin b
FI893405L (fi) Menetelmä kinoloniyhdisteiden valmistamiseksi
FI891711L (fi) Menetelmä diorganodialkoksisilaanien valmistamiseksi
NO172446C (no) Fremgangsmaate for fremstilling av et ikke-naturlig avermectin
KR860005574A (ko) 뉴클레오시드 유도체의 제조방법
FI885489L (fi) Menetelmä amikasiinin valmistamiseksi
FI884983L (fi) Menetelmä terapeuttisesti käyttökelpoisten LL-E33288 kompleksi-disulfidianalogien valmistamiseksi
FI883661L (fi) Menetelmä eetteröityjen tärkkelysten valmistamiseksi
FI871670L (fi) Menetelmä osseiini-hydroksiapatiittiyhdisteen valmistamiseksi
FI885880L (fi) Menetelmä virusvastaisen yhdisteen valmistamiseksi
FI891677L (fi) Menetelmä 4-demetoksidaunomysinonin valmistamiseksi
KR860004922A (ko) N-포르밀-α-아스파르틸페닐알라닌의 제조방법
FI881544L (fi) Menetelmä mekaanisen massan valmistamiseksi
KR860004919A (ko) 뉴클레오시드 유도체의 제조방법
KR870001175A (ko) 5-치환된-6-아미노피리미딘 유도체의 제조방법
FI885045L (fi) Menetelmä polynukleotidien valmistamiseksi
FI882894L (fi) Menetelmä 2-kinoksalinoliyhdisteen valmistamiseksi
KR890010537A (ko) 어라인먼트방법
FI901734A0 (fi) Menetelmä polyketonien valmistamiseksi
FI882314L (fi) Halogeeni-imidien valmistusmenetelmä

Legal Events

Date Code Title Description
BB Publication of examined application
FG Patent granted

Owner name: PFIZER INC.

MA Patent expired